Brainstorm Cell Therapeutics Secures $1 Million in Private Placement Funding
PUBLIC · BCLIFeb 13, 2026
Amount Raised
$1 Million
Round Type
Post-IPO Equity
New YorkBiotechnologyHealth CareTherapeuticsresearch
Investors
Accredited Investor
Description
On February 9, 2026, Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement with an accredited investor. The agreement involves two closings, with a total subscription amount of $1,000,000 for shares of the company's common stock. The purchase will occur in two separate closings of $500,000 each.
Company Information
Company
Brainstorm Cell Therapeutics
Location
1325 Avenue of Americas, 28th Floor
New York, New York, United States
About
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
Fundz sees it the moment Brainstorm Cell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyHealth CareTherapeuticsresearch